On worldwide sales Once the Phase 2 study has been completed and based on a review of the data, GSK may choose to take responsibility for all future development and commercialization of the product, – source. Unigene Laboratories.. About Unigene GSK AgreementOn the 10th December 2010 Unigene entered into an amended and exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women under the conditions of. Amended and restated agreement, Unigene manufacture manufacture of PTH and the implementation of the Phase 2 study.
Unigene doses first patient in Phase 2 Oral PTH Study for the treatment of osteoporosis in postmenopausal womenUnigene Laboratories announced a leader in the design, delivery, manufacture and development of peptide-based therapeutic dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women. Unigene developed its oral PTH in collaboration with GlaxoSmithKline as part of an exclusive worldwide license agreement..The securities ‘ ‘ oppression of antitumor immunity with Fibroblast Activation Protein – express stroma.’is in the 5th November 2010 issue of Science, publish. On.